Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the mucosa, the innermost lining of the intestinal wall in the large bowel (i.e., the colon and rectum). The disease is typically diagnosed between age 15 and 35 and causes longlasting inflammation and ulcers in the digestive tract. Symptoms may include frequent diarrhea, sometimes with blood or pus, abdominal and/or rectal pain, weight loss, and fatigue. When the disease affects children, it can have a detrimental impact on growth, nutritional status, and psychosocial development. It is estimated that approximately 900,000 individuals in
the United States have UC; the economic burden of UC is significant, ranging between $15-32 billion per year, including lost productivity at work and/or school

Treatments of Interest:

  • Vedolizumab (Entyvio®, Takeda)
  • Infliximab (Remicade®, Janssen)
  • Infliximab-dyyb (Inflectra®, Pfizer)
  • Infliximab-abda (Renflexis®, Merck)
  • Adalimumab (Humira®, AbbVie)
  • Golimumab (Simponi®, Janssen)
  • Tofacitinib (Xeljanz®, Pfizer)
  • Ustekinumab (Stelara®, Janssen)

Date of Review: September 2020

For questions, please contact info@icer.org

View the Key Stakeholders List.

Final Documents

Below you will find the final documents from the assessment review process: